G
MRNA icon

Gainplan’s Moderna MRNA Stock Holding History

Gainplan’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1,693
Closed -$403K – 68
2021
Q2 		$403K Buy
+1,693
New +$303K 0.16% 51

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Coatue Management
Coatue Management New York $48.6B AUM 94.27% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Gainplan's MRNA Position: Q3 2021 in Review

Gainplan sold out of Moderna (MRNA) in Q3 2021, closing a stake of 1,693 shares — an estimated $403K sold.

Gainplan first reported a position in MRNA in Q2 2021 and held it in 1 quarter. The position peaked at $403K in Q2 2021. 1,141 funds tracked by Wall St. Rank hold MRNA as of Q3 2021.

  • Gainplan reported no remaining Moderna position as of Q3 2021 after selling out during the quarter.
  • Gainplan sold 1,693 Moderna shares in Q3 2021, an estimated $403K.
  • Gainplan first reported a position in Moderna in Q2 2021 and held it in 1 quarter.
  • Gainplan's Moderna position peaked at $403K in Q2 2021.
  • 1,141 funds tracked by Wall St. Rank held Moderna as of Q3 2021.

Based on Gainplan's 13F filing for Q3 2021, filed 12 Nov 2021.